Acridinediamine | 129947-07-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: Acridinediamine
• 英文别名: acridine-1,2-diamine
• CAS: 129947-07-5
• 化学式: C₁₃H₁₁N₃
• 分子量: 209.25
• InChiKey: VNDXKMITHCJCOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.9
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] TARGETED DELIVERY AND PRODRUG DESIGNS FOR PLATINUM-ACRIDINE ANTI-CANCER COMPOUNDS AND METHODS THEREOF<br/>[FR] ADMINISTRATION CIBLÉE ET CONCEPTIONS DE PROMÉDICAMENTS POUR COMPOSÉS ANTICANCÉREUX À BASE DE PLATINE ET D'ACRIDINE ET MÉTHODES ASSOCIÉES
  申请人：WAKE FOREST SCHOOL OF MEDICINE

  公开号：WO2013033430A1

  公开（公告）日：2013-03-07

  Acridine containing cispiaiin compounds have been disclosed that show greater efficacy against cancer than other cisplatin compounds. Methods of delivery of those more effective eisp!aiin compounds to the nucleus in cancer ceils is disclosed using one or more amino acids, one or more sugars, one or more polymeric ethers, C i^aikylene-phenyl-NH-C(0)-R.15, folic acid, av03 iniegriii RGD binding peptide, tamoxifen, endoxifen, epidermal growth factor receptor, antibody conjugates, kinase inhibitors, diazoles, triazol.es, oxazoies, erlotinib, and/or mixtures thereof; wherein R]§ is a peptide.

  含有环丙啶结构的吖啶类化合物已被披露，显示出比其他顺铂类化合物更有效地对抗癌症。使用一种或多种氨基酸、一种或多种糖、一种或多种聚合醚、C i^aikylene-phenyl-NH-C(0)-R.15、叶酸、av03整合RGD结合肽、他莫昔芬、恩多西芬、表皮生长因子受体、抗体结合物、激酶抑制剂、二唑类化合物、三唑类化合物、噁唑类化合物、厄洛替尼和/或它们的混合物将这些更有效的吖啶类化合物传递到癌细胞核中的方法被披露；其中R]§是一个肽。
• [EN] AZETIDINE-SUBSTITUTED FLUORESCENT COMPOUNDS<br/>[FR] COMPOSÉS FLUORESCENTS À SUBSTITUTION AZÉTIDINE
  申请人：HUGHES HOWARD MED INST

  公开号：WO2015153813A1

  公开（公告）日：2015-10-08

  The presently-disclosed subject matter includes azetidine-substituted fluorescent compounds, where the compounds may be used as probes, dyes, tags, and the like. The presently-disclosed subject matter also includes kits comprising the same as well as methods for using the same to detect a target substance.

  目前公开的题材包括取代的荧光化合物，其中化合物可用作探针、染料、标签等。目前公开的题材还包括包含相同成分的试剂盒以及使用相同成分检测目标物质的方法。
• BIODEGRADABLE HYBRID POLYMERS USABLE IN MEDICAL TECHNOLOGY OR IN BIOLOGY, STARTING SILANES THEREFOR, AND PREPARATION PROCESS THEREFOR AND USES THEREOF
  申请人：Fraunhofer-Gesellschaft Zur Forderung der Angewandten Forschung E.V.

  公开号：US20170313726A1

  公开（公告）日：2017-11-02

  The invention relates to a silane or silane mixture obtainable by reacting a hydrolysable silane of the formula (A): SiR4 in which R is a hydrolytically condensable group or hydroxyl with a compound R*(OH)x where x is 1, 2, 3 or greater 3, where R* has a straight-chain or branched hydrocarbon skeleton which, according to the number x, is monovalent, divalent, trivalent or multivalent, and has a hydrocarbonaceous chain interrupted by at least two —C(O)O— groups, wherein there are a maximum of 8 successive carbon atoms in the individual hydrocarbon units formed by interruptions within this chain and the, or in the case of branched structures at least one, end of the hydrocarbonaceous chain at the opposite end to the sole hydroxyl group or one of the hydroxyl groups bears an organically polymerizable group, wherein the alcohol is otherwise unsubstituted or has further substituents. The invention further relates to an organically modified silica polycondensate formed as a result of hydrolytic condensation of the silane or silane mixture and optionally a subsequent organic polymerization of the organically polymerizable groups, with optional addition of an organic, at least difunctional compound to the silica polycondensate prior to the organic polymerization.

  该发明涉及一种硅烷或硅烷混合物，其可通过将具有以下式(A)的可水解硅烷与化合物R*(OH)x反应而得到：SiR4，其中R是一个可水解缩聚基团或羟基，化合物R*具有直链或支链烃骨架，根据数目x，该骨架是一价、二价、三价或多价的，并且具有至少两个—C(O)O—基团中断的烃链，其中在该链内由中断形成的各个烃单元中最多有8个连续的碳原子，或者在支链结构的情况下，至少有一个烃链的末端，与唯一的羟基或其中一个羟基相对的末端具有一个有机聚合基团，其中醇在其他方面未被取代或具有进一步的取代基。该发明还涉及一种有机改性的二氧化硅缩聚物，其是由硅烷或硅烷混合物的水解缩聚以及有机聚合基团的随后有机聚合形成的，有机聚合之前在有机聚合之前向二氧化硅缩聚物中添加有机的至少二官能化合物。
• [EN] PLATINUM ACRIDINE ANTI-CANCER COMPOUNDS AND METHODS THEREOF<br/>[FR] COMPOSÉS ANTICANCÉREUX À BASE DE PLATINE ET D'ACRIDINE ET PROCÉDÉS POUR LES UTILISER
  申请人：UNIV WAKE FOREST

  公开号：WO2010048499A1

  公开（公告）日：2010-04-29

  Acridine containing cisplatin compounds are disclosed that show greater efficacy against cancer than other cisplatin compounds.

  揭示了含有铂的吖啶类化合物，对癌症的疗效优于其他铂类化合物。
• [EN] PROTEIN CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À UN EXCIPIENT PROTÉIQUE
  申请人：ASCENDIS PHARMA AS

  公开号：WO2013024049A1

  公开（公告）日：2013-02-21

  The present invention relates to water-soluble protein carrier- linked prodrugs wherein the protein carrier comprises an amino acid sequence consisting of at least 100 amino acid residues forming random coil conformation and comprising alanine, serine and proline residues. It further relates to pharmaceutical compositions comprising said water-soluble protein carrier- linked prodrugs, their use as a medicament as well as methods of treatment and administration.

  本发明涉及水溶性蛋白载体连接的前药，其中蛋白载体包括至少100个氨基酸残基组成的氨基酸序列，形成随机卷曲构象，包括丙氨酸、丝氨酸和脯氨酸残基。还涉及包含上述水溶性蛋白载体连接的前药的药物组合物，它们作为药物的用途，以及治疗和管理的方法。